Scarica l'app Stockscreener
46.71
0.06%
0.03
Dopo l'orario di chiusura:
46.71
Precedente Chiudi:
$46.68
Aprire:
$46.68
Volume 24 ore:
4.43M
Relative Volume:
0.94
Capitalizzazione di mercato:
$3.52B
Reddito:
-
Utile/perdita netta:
$-275.16M
Rapporto P/E:
-12.01
EPS:
-3.89
Flusso di cassa netto:
$-221.15M
1 W Prestazione:
+0.49%
1M Prestazione:
+1.02%
6M Prestazione:
+12.61%
1 anno Prestazione:
+9.62%
Intervallo 1D:
$46.66
$46.75
Intervallo di 1 settimana:
$46.46
$46.77
Portata 52W:
$28.21
$62.00
Springworks Therapeutics Inc Stock (SWTX) Company Profile
Nome
Springworks Therapeutics Inc
Settore
Industria
Telefono
203-883-9490
Indirizzo
100 WASHINGTON BOULEVARD, STAMFORD, CT
Confronta SWTX con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
SWTX
Springworks Therapeutics Inc
|
46.71 | 3.50B | 0 | -275.16M | -221.15M | -3.89 |
|
ONC
Beone Medicines Ltd Adr
|
245.58 | 26.10B | 3.81B | -644.79M | -669.77M | -6.24 |
|
VRTX
Vertex Pharmaceuticals Inc
|
442.05 | 111.96B | 11.10B | -988.90M | -1.26B | -3.92 |
|
AKTX
Akari Therapeutics Plc Adr
|
1.35 | 42.96M | 0 | 0 | 0 | 0.00 |
|
VRNA
Verona Pharma Plc Adr
|
81.20 | 6.39B | 0 | -153.72M | -103.81M | -2.00 |
|
REGN
Regeneron Pharmaceuticals Inc
|
490.28 | 63.52B | 14.09B | 4.50B | 2.96B | 39.28 |
Springworks Therapeutics Inc Stock (SWTX) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2024-11-20 | Iniziato | Evercore ISI | Outperform |
| 2024-02-05 | Iniziato | Guggenheim | Buy |
| 2022-12-01 | Iniziato | BofA Securities | Buy |
| 2021-01-19 | Reiterato | H.C. Wainwright | Buy |
| 2020-10-29 | Reiterato | H.C. Wainwright | Buy |
| 2020-05-05 | Iniziato | Barclays | Overweight |
| 2020-03-19 | Aggiornamento | H.C. Wainwright | Neutral → Buy |
| 2020-03-04 | Downgrade | H.C. Wainwright | Buy → Neutral |
| 2020-01-21 | Reiterato | H.C. Wainwright | Buy |
| 2019-12-04 | Iniziato | H.C. Wainwright | Buy |
| 2019-10-08 | Iniziato | Cowen | Outperform |
| 2019-10-08 | Iniziato | Goldman | Buy |
| 2019-10-08 | Iniziato | JP Morgan | Overweight |
| 2019-10-08 | Iniziato | Wedbush | Outperform |
Mostra tutto
Springworks Therapeutics Inc Borsa (SWTX) Ultime notizie
Nuveen Asset Management LLC Has $6.64 Million Holdings in SpringWorks Therapeutics, Inc. (NASDAQ:SWTX) - MarketBeat
BNP Paribas Financial Markets Purchases Shares of 9,719 SpringWorks Therapeutics, Inc. (NASDAQ:SWTX) - MarketBeat
Promising Growth Stocks To Research – May 28th - Defense World
ProShare Advisors LLC Has $827,000 Position in SpringWorks Therapeutics, Inc. (NASDAQ:SWTX) - MarketBeat
SpringWorks Therapeutics, Inc. (NASDAQ:SWTX) Given Average Recommendation of "Hold" by Analysts - MarketBeat
Deutsche Bank AG Purchases 19,540 Shares of SpringWorks Therapeutics, Inc. (NASDAQ:SWTX) - MarketBeat
Merck, SpringWorks receive German antitrust approval for their deal - MLex
SpringWorks Therapeutics (NASDAQ:SWTX) Sees Unusually-High Trading VolumeHere's What Happened - MarketBeat
Palisades Investment Partners LLC Purchases 12,154 Shares of SpringWorks Therapeutics, Inc. (NASDAQ:SWTX) - MarketBeat
Bank of America Corp DE Reduces Holdings in SpringWorks Therapeutics, Inc. (NASDAQ:SWTX) - MarketBeat
SpringWorks Therapeutics (SWTX) Surged on Acquisition News - Insider Monkey
BNP Paribas Financial Markets Makes New $351,000 Investment in SpringWorks Therapeutics, Inc. (NASDAQ:SWTX) - Defense World
SpringWorks Gets CHMP Nod for Mirdametinib in Rare Disease - Nasdaq
142,300 Shares in SpringWorks Therapeutics, Inc. (NASDAQ:SWTX) Bought by Zimmer Partners LP - MarketBeat
SpringWorks Therapeutics’ SWOT analysis: biotech stock faces acquisition challenges - Investing.com
Growth Stocks To Consider – May 23rd - Defense World
Growth Stocks To ConsiderMay 23rd - MarketBeat
(SWTX) Investment Analysis - news.stocktradersdaily.com
SpringWorks Therapeutics receives positive CHMP opinion for Mirdametinib for the treatment of adult and paediatric patients with NF1-PN | Health & Wellbeing | Lifestyle - The Phoenix Newspaper UK
SpringWorks Therapeutics (NASDAQ:SWTX) Sees Large Volume Increase – Time to Buy? - Defense World
Woodline Partners LP Raises Holdings in SpringWorks Therapeutics, Inc. (NASDAQ:SWTX) - MarketBeat
SpringWorks Therapeutics erhält positive CHMP-Stellungnahme für Mirdametinib zur Behandlung erwachsener und pädiatrischer Patienten mit NF1-PN - GlobeNewswire Inc.
Rafferty Asset Management LLC Has $4.44 Million Stake in SpringWorks Therapeutics, Inc. (NASDAQ:SWTX) - MarketBeat
Velan Capital Investment Management LP Acquires Shares of 185,520 SpringWorks Therapeutics, Inc. (NASDAQ:SWTX) - MarketBeat
Tema Etfs LLC Takes $1.11 Million Position in SpringWorks Therapeutics, Inc. (NASDAQ:SWTX) - MarketBeat
SpringWorks’ drug nears EU approval for neurofibromatosis treatment By Investing.com - Investing.com South Africa
SpringWorks Therapeutics (SWTX) Gains EMA Panel Support for Mird - GuruFocus
SpringWorks gets EU endorsement for genetic disorder treatment - Seeking Alpha
SpringWorks’ drug nears EU approval for neurofibromatosis treatment - Investing.com Australia
Springworks Therapeutics Says Mirdametinib Recommended by EU Panel for Treating Plexiform Neurofibromas - marketscreener.com
SpringWorks Therapeutics Receives Positive CHMP Opinion For Mirdametinib For The Treatment Of Adult And Pediatric Patients With NF1-PN - marketscreener.com
SpringWorks: CHMP Adopts Positive Opinion For Mirdametinib - Nasdaq
SpringWorks Therapeutics Receives Positive CHMP Opinion for Mirdametinib for the Treatment of Adult and Pediatric Patients with NF1-PN - The Manila Times
SpringWorks Therapeutics Receives Positive CHMP Opinion for Mird - GuruFocus
SpringWorks Therapeutics (SWTX) Receives Positive Opinion from E - GuruFocus
SpringWorks Therapeutics Receives Positive CHMP Opinion for Mirdametinib for the Treatment of Adult and Pediatric Patients with NF1-PN | SWTX Stock News - GuruFocus
SpringWorks Therapeutics (SWTX) Receives Positive Opinion from EMA for Mirdametinib | SWTX Stock News - GuruFocus
SpringWorks Therapeutics Reports Positive CHMP Opinion for Mirdametinib as Potential First Therapy for NF1-PN in EU - Nasdaq
SpringWorks Therapeutics Inc. (SWTX) Receives Positive CHMP Opinion for Mirdametinib for the Treatment of Adult and Pediatric Patients with NF1-PN - StreetInsider
SpringWorks Therapeutics Receives Positive CHMP Opinion for - GlobeNewswire
Breakthrough NF1-PN Treatment Scores 52% Response Rate in Children as EU Approval Looms - Stock Titan
SpringWorks Therapeutics, Inc. (NASDAQ:SWTX) Receives Consensus Recommendation of “Hold” from Analysts - Defense World
Deutsche Bank AG Increases Position in SpringWorks Therapeutics, Inc. (NASDAQ:SWTX) - Defense World
SpringWorks Therapeutics, Inc. (NASDAQ:SWTX) Shares Sold by Ensign Peak Advisors Inc - MarketBeat
SpringWorks Therapeutics, Inc. (NASDAQ:SWTX) Shares Sold by Bank of America Corp DE - Defense World
Sphera Funds Management LTD. Acquires Shares of 100,000 SpringWorks Therapeutics, Inc. (NASDAQ:SWTX) - MarketBeat
D. E. Shaw & Co. Inc. Sells 336,949 Shares of SpringWorks Therapeutics, Inc. (NASDAQ:SWTX) - MarketBeat
Patient Square Capital LP Buys Shares of 93,137 SpringWorks Therapeutics, Inc. (NASDAQ:SWTX) - MarketBeat
Northern Trust Corp Buys 52,908 Shares of SpringWorks Therapeutics, Inc. (NASDAQ:SWTX) - MarketBeat
Ameriprise Financial Inc. Acquires 173,222 Shares of SpringWorks Therapeutics, Inc. (NASDAQ:SWTX) - MarketBeat
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates - GlobeNewswire
Springworks Therapeutics Inc Azioni (SWTX) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
1.89%
3.74%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):